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Left ventricular mass monitoring in the follow-up of dialysis
patients: Prognostic value of left ventricular hypertrophy pro-
gression.
Background. Regression of left ventricular hypertrophy
(LVH) in the setting of a well-planned intervention study has
been associated with longer survival in hemodialysis patients.
Whether changes in left ventricular mass (LVM) in clinical prac-
tice predict survival and cardiovascular events in these patients
is still unknown.
Methods. In a prospective study in 161 hemodialysis patients
we tested the prognostic value of changes in LVM on survival
and incident cardiovascular events. Echocardiography was per-
formed twice, 18 ± 2 SD months apart. Changes in LVM occur-
ring between the first and the second echocardiographic study
were then used to predict mortality and cardiovascular events
during the ensuing 29 ± 13 months. The prognostic value of
LVM changes was tested in a multivariate Cox’s model with
LVM index (LVMI) (expressed as LVM/height2.71), included as
a covariate to control for regression to the mean.
Results. The rate of increase of LVMI was significantly
(P = 0.029) higher in patients with incident cardiovascular
events than in those without such events. Accordingly, cardio-
vascular event-free survival in patients with changes in LVMI
below the 25th percentile was significantly (P = 0.004) higher
than in those with changes above the 75th percentile. In a mul-
tiple Cox regression analysis, including age, diabetes, smoking,
homocysteine, 1 g/m2.7/month increase in LVMI was associated
with a 62% increase in the incident risk of fatal and nonfatal
cardiovascular events [hazard ratio 1.62 (95% CI 1.13–2.33),
P = 0.009].
Conclusion. Changes in LVMI have an independent prognos-
tic value for cardiovascular events and provide scientific support
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to the use of repeated echocardiographic studies for monitoring
cardiovascular risk in dialysis patients.
There is now consistent evidence that left ventricular
hypertrophy (LVH) has an important prognostic value
in patients with end-stage renal disease (ESRD) [1–4].
LVH in ESRD is a disorder of multifactorial origin [5]
and hypertension, anemia, hyperparathyroidism, chronic
volume expansion, and emerging risk factors like inflam-
mation [6, 7], hyperhomocysteinemia [8], high sympa-
thetic activity [9] and accumulation of the endogenous
inhibitor of nitric oxide synthase (NOS) asymmetrical
dimethylarginine (ADMA) [10] have been implicated in
this alteration. Although the mechanisms responsible for
the strong link between high left ventricular mass (LVM)
and cardiovascular complications are still incompletely
understood, LVM is generally considered as an integra-
tor of the long-term effects of several risk factors [11].
Serial echocardiographic studies by Foley et al [12]
demonstrated that cardiac enlargement is not halted by
the institution of dialysis treatment. This important obser-
vation suggests that repeated echocardiographic record-
ings may provide additional prognostic information in
dialysis patients. However, the prognostic value of LVM
in ESRD has been examined almost exclusively in fol-
low up studies (i.e., by relating a single LVM mea-
surement made at the start of the study with mortality
and incident cardiovascular events [1–3]). The possibil-
ity that serial measurements of LVM may give important
prognostic information is supported by a multifactorial
intervention study by London et al [4] showing that in-
tensive treatment of risk factors for LVH produces a
clear regression in LVM index (LVMI) and reduces all-
cause and cardiovascular mortality. On the other hand, in
the general population worsening of LVH measured by
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Table 1. Demographic, somatometric, clinical, biochemical, and echocardiographic data of patients in the original study cohort and in those who
repeated the echocardiographic study
Patients who repeated
echocardiography
(N = 161)
Original cohort P value
(N = 203) First visit Second visit (second vs. first visit)
Age years 58.9 ± 14.9 58.0 ± 15.1 60.3 ± 15.0 <0.001
Males number 113 (56%) 90 (56%) 90 (56%) 1.00
Body mass index kg/m2 24.5 ± 4.4 24.4 ± 4.3 24.4 ± 4.2 0.76
Diabetics number 28 (14%) 18 (11%) 18 (11%) 1.00
Smokers number 78 (38%) 57 (35%) 57 (35%) 1.00
Patients on antihypertensive therapy number 78 (38%) 59 (37%) 55 (34%) 0.73
Systolic blood pressure mm Hg 140.4 ± 24.8 138.4 ± 24.8 135.9 ± 26.4 0.11
Diastolic biood pressure mm Hg 76.3 ± 13.2 76.1 ± 13.7 74.9 ± 13.4 0.21
Heart rate beats/min 78.6 ± 10.4 78.6 ± 9.9 79.9 ± 10.9 0.12
Hemoglobin g/dL 10.6 ± 1.9 10.5 ± 1.8 11.0 ± 1.6 0.002
Albumin g/dL 4.2 ± 0.5 4.2 ± 0.5 3.6 ± 0.5 <0.001
Cholesterol mg/dL 206.9 ± 56.1 203.0 ± 55.0 175.4 ± 46.4 <0.001
Calcium × Phosphate mmo2/L2 4.54 ± 1.16 4.54 ± 1.20 4.29 ± 1.18 0.01
C-reactive protein mg/L 7.7 (3.4–16.3) 7.4 (3.4–16.1) NA —
Homocysteine lmol/L 26.4 (19.4–42.3) 24.7 (18.3–40.7) NA —
ADMA lmol/L 2.61 (1.58–3.96) 2.44 (1.56–3.72) NA —
Noradrenaline pmol/L 3.12 (1.76–5.67) 3.13 (1.70–5.62) NA —
Kt/V 1.22 ± 0.27 1.23 ± 0.27 1.32 ± 0.25 <0.001
Left ventricular end diastolic diameter cm 5.04 ± 0.66 5.05 ± 0.66 5.14 ± 0.64 0.001
Mean wall thickness cm 1.14 ± 0.20 1.11 ± 0.19 1.14 ± 0.16 <0.001
Relative wall thickness 0.44 ± 0.11 0.43 ± 0.10 0.43 ± 0.08 0.68
Left ventricular ejection fraction % 58.8 ± 9.8 58.9 ± 10.0 58.0 ± 10.0 0.29
Left ventricular mass index g/m2.7 61.0 ± 18.7 59.2 ± 18.1 63.2 ± 19.3 <0.001
ADMA is asymmetrical dimethylarginine; NA is not available.
Data are mean ± SD, median (interquartile range) or percent frequency. Comparisons between groups were made by paired t test or chi-squared test, as appropriate.
electrocardiography [13] is associated with a higher
risk of cardiovascular events. Likewise, in patients
with essential hypertension, persistence or worsening of
echocardiographic LVH is associated with a higher risk
for subsequent cardiovascular events [14]. Whether LVH
progression has a prognostic value in clinical practice in
ESRD (i.e., in a context different from that of a well-
planned intervention study aimed at reducing LVM) is
still undefined. The issue is of relevance because LVH is
now regarded as a valid surrogate end point to be targeted
in intervention studies in dialysis patients [15]. The pur-
pose of the present study was to determine the prognostic
significance of serial measurements of LVM in hemodial-
ysis patients who attended the baseline and follow up
echocardiographic measurements in the Cardiovascular
Risk Extended Evaluation in Dialysis (CREED) study
patients. To this aim we related changes in LVM to all-
cause mortality and incident cardiovascular events and
tested whether these relationships are independent of
baseline LVM, previous cardiovascular events, and of a
series of traditional and nontraditional risk factors.
METHODS
Protocol
The protocol was in conformity to the ethical guidelines
of our institutions and informed consent was obtained
from each participant. All studies were performed during
a nondialysis day, between 8:00 a.m. and 1:00 p.m.
Original study cohort
The original hemodialysis cohort was formed by 231
patients (127 males and 104 females). These patients had
been on regular dialysis treatment for at least 6 months
(median duration 41 months, interquartile range 21 to
106 months). The enrollment criteria in the CREED co-
hort were no history of congestive heart failure (defined
as dyspnea in addition to two of the following conditions:
raised jugular pressure, bibasilar crackles, pulmonary ve-
nous hypertension or interstitial edema on chest x ray,
requiring hospitalization or extra ultrafiltration [16], ejec-
tion fraction >35%, and no intercurrent or terminal ill-
nesses. Twenty-eight patients were excluded because of
low quality echocardiographic recordings. Thus, 203 pa-
tients (113 males and 90 females) could be enrolled in this
study. The main demographic and clinical characteristics
of the cohort are detailed in Table 1. All patients were
virtually anuric (24-hour urine volume <200 mL/day)
and were being treated three times a week with stan-
dard bicarbonate dialysis (sodium 138 mmol/L, HCO3
35 mmol/L, potassium 1.5 mmol/L, calcium 1.25 mmol/L,
magnesium 0.75 mmol/L) and cuprophan or semisyn-
thetic membranes (dialysis filters surface area 1.1 to
1.7 m2). One hundred and thirty patients were on
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treatment with erythropoietin. Seventy-eight patients
were being treated with antihypertensive drugs [54
on monotherapy with angiotensin-converting enzyme
(ACE) inhibitors, angiotensin type 1 antagonists, calcium
channel blockers, and alpha and beta blockers and 24 on
double or triple therapy with various combinations of
these drugs).
Patients who repeated the echocardiographic study
Thirty patients out of 203 of the original cohort
died before the time at which the second echocardio-
graphic study was performed, four patients underwent
renal transplantation and eight patients could not repeat
echocardiography for logistic reasons. Therefore, 161 pa-
tients were left for this study aimed at defining the prog-
nostic value of changes in LVMI (see Table 1). In the
present analysis, we considered the patients who attended
the baseline and the second echocardiographic study con-
templated in the CREED study.
Follow-up
After the initial assessment, patients were followed-up
by the nephrologists participating in the study (CREED
investigators). The study was purely observational and
therefore it did not contemplate changes in treatment pol-
icy. The second echocardiographic study was performed
from 13.6 to 22.6 months (average 18 months) after the
baseline study.
The overall duration of the follow-up was 39 ±
19 months. The duration of follow-up after the second
echocardiographic study was 29 ± 13 months. Since in
the present study we were interested in establishing the
prognostic value of changes in LVMI, all survival analyses
reported herein apply to the follow-up after the second
echocardiographic study (see also the Methods section,
Statistical Analysis).
End point evaluation
During the follow-up cardiovascular events
(electrocardiographic-documented anginal episodes
and myocardial infarction, heart failure, electrocardio-
graphic-documented arrhythmia, transient ischemic
attacks, stroke, and other thrombotic events) and death
were accurately recorded. Each death was reviewed
and assigned an underlying cause by a panel of five
physicians. As a part of the review process, all available
medical information about each death was collected.
This information always included study and hospital-
ization records. In the case of an out-of-hospital death
family members were interviewed by telephone to
better ascertain the circumstances surrounding death.
As alluded to before, for the purpose of establishing the
prognostic value of LVH progression, only events (death
and cardiovascular events) occurring after the second
echocardiogram were considered.
Echocardiography
These studies were performed in a nondialysis day
within 2 hours after blood sampling (see below). At the
time of the echocardiographic examination, investigators
involved in echocardiographic studies (F.B. and G.G.)
were unaware of patients’ clinical data. LVM was cal-
culated according to the Devereux formula and indexed
to height2.7 (LVMI) [17]. The height-based indexing of
LVM was specifically chosen to minimize any potential
distortion attributable to extracellular volume expansion
(surface area indexing being weight-sensitive) [3]. Mean
wall thickness (MWT) was calculated by the standard
formula [MWT = (posterior wall thickness + interven-
tricular septum thickness)/2]. The relative wall thickness
(RWT) (2 · posterior wall thickness/left ventricular end
diastolic diameter) was also calculated, as an index of
the left ventricular geometric pattern. Changes in LVMI
were quantified by subtracting LVMI at the second study
from that obtained at baseline study and by factoring this
difference for the time interval between the two studies.
Biochemical measurements
Blood sampling for the measurement of routine and
special biochemical measurements were performed be-
fore echocardiographic studies. The methods used for
the determination of serum C-reactive protein (CRP),
plasma norepinephrine, ADMA, and homocysteine were
detailed in previous publications [9, 10].
Blood pressure measurements
Blood pressures were calculated as the average value
of all recordings [12 measurements (i.e., 3/week)] taken
predialysis during the month preceding the study [18].
Statistical analysis
Data are expressed as mean ± SD (normally
distributed data), median and interquartile range
(nonnormally distributed data) or as percent frequency.
Comparisons between groups were made by a test for
trend and within subject comparisons by the paired
t test or the chi-square test, as appropriate. Probability
of survival was analyzed using the Kaplan-Meier survival
analysis and by the multivariate Cox proportional haz-
ards model. In these analyses patients were divided into
three groups on the basis of the 25th and the 75th per-
centile of LVMI changes. For patients who had multiple
events, survival analysis was restricted to the first event.
The independent prognostic value of LVMI changes for
mortality and cardiovascular events was tested by mul-
tivariate Cox regression analysis. Multivariate models
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were constructed by starting with all covariates that
were associated (P < 0.05) with the outcome measures
(mortality and cardiovascular events) at univariate Cox
regression analysis. To obtain parsimonious models, co-
variates that independently contributed to the predic-
tion of these outcomes were identified by a backward
approach in models where we always forced baseline
LVMI. The following covariates were initially considered
for these analyses: baseline LVMI and LVMI change, age,
gender, diabetes; baseline systolic pressure and heart rate,
and their changes from baseline to the follow up visit;
previous cardiovascular events, antihypertensive therapy
at baseline and follow-up, smoking habits, serum choles-
terol, hemoglobin, albumin, Ca × P product, Kt/V, and
the change in these covariates at follow-up. Furthermore,
we also tested emerging risk factors (CRP, homocysteine,
ADMA, and norepinephrine), which were available at
baseline visit only. By this approach we constructed mod-
els of adequate statistical power (at least 10 events for
each variable in the final model). The assumption of lin-
earity for the Cox models was examined through visual
inspection and no violation of proportional hazards was
found. Missing values (albumin, N = 4; albumin, N = 2;
cholesterol, N = 4; cholesterol, N = 8; calcium × phos-
phate, N = 3; calcium x phosphate, N = 8; CRP, N = 3;
homocysteine, N = 3; ADMA, N = 4; and hemoglobin,
N = 1) were set at the average value of the correspond-
ing variable. Hazard ratios (HR) and their 95% CI were
calculated using the estimated regression coefficients and
their standard errors in the Cox regression analysis. All
calculations were made using a standard statistical pack-
age (SPSS for Windows, version 9.0.1, Chicago, IL, USA).
RESULTS
The main somatometric, clinical, hemodynamic, bio-
chemical and echocardiographic data at the baseline
and at the second echocardiographic study are shown
in Table 1. Arterial pressure showed a minor reduction.
Hemoglobin, serum cholesterol and the administered
dialysis dose (Kt/V) improved significantly while serum
albumin showed a 14% decrease. Overall, there was a sig-
nificant worsening in LVMI and in all anatomic param-
eters of the left ventricle while left ventricular ejection
fraction did not change. Figure 1 shows absolute changes
in echocardiographic parameters as related to their rel-
ative baseline measurements. LVMI changes as well as
changes in the other echocardiographic parameters were
more pronounced in patients in the first group (i.e., those
with values <25th percentile) and declined consistently
from the first to the third group (those with values >75th
percentile). This phenomenon indicates that the baseline
measurement is a confounder for subsequent changes.
In other words, changes were much attenuated in pa-
tients with initially higher values because, due to the phe-
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Fig. 1. Relationship between baseline echocardiographic measure-
ments of the left ventricle and their changes at the second examina-
tion. Abbreviations are: LVMI, left ventricular mass index; LVEDD,
left ventricular end diastolic diameter; MWT, mean wall thickness.
nomenon of the regression to the mean, extreme values
tend to be less extreme repeated measurements. Thus in
patients with higher initial LVMI the appreciation of any
progression in LVH (a biologic phenomenon) is attenu-
ated by a purely statistical phenomenon of opposite sign
(regression to the mean).
LVH progression, all-cause death, and cardiovascular
morbidity: Kaplan-Meier analysis
After the second echocardiographic study, 58 patients
died. Sixty-six patients had one or more cardiovascular
events, which were fatal in 45 cases. The rate of increase
in LVMI was higher (P = 0.01) in patients who died dur-
ing the follow-up (median 0.25 g/m2.7/month, interquar-
tile range 0.08 to 0.72 g/m2.7/month) than in those who
survived (0.15 g/m2.7/month, −0.16 to 0.44 g/m2.7/month)
and in a Kaplan-Meier analysis there was a graded rela-
tionship between the rate of increase in LVMI and the
incidence of death so that the relative risk of patients
with LVMI >75th percentile (HR 2.56, 95% CI 1.94–
3.31) was substantially higher than that of patients with
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Fig. 2. Kaplan-Meier curves for all-cause mortality (A) and for fatal and nonfatal cardiovascular events (B). Patients were divided into three groups
on the basis of the 25th and the 75th percentile of left ventricular mass index (LVMI) changes.
Table 2. Multivariate analysis of all-cause death
Units of increase Hazard ratio (95% CI) P value
Changes in LVMI
<25th percentile <−0.10 g/m2.7/month 1a
25–75th percentile −0.10- 0.50 g/m2.7/month 1.60 (0.70–3.66) 0.26
>75th percentile >0.50 g/m2.7/month 3.07 (1.34–7.05) 0.008
Age 1 year 1.05 (1.03–1.08) <0.001
Male gender 2.42 (1.36–4.34) 0.003
Previous cardiovascular eventsb 1.58 (0.91–2.72) 0.10
Baseline LVMI 1.01 (0.99–1.03) 0.12
LVMI is left ventricular mass index; ADMA is asymmetrical dimethylarginine.
aReference group.
bEvents occurring in between the two echocardiographic studies were considered (together with cardiovascular events that occurred before the study) as “previous
cardiovascular events” and the variable was introduced into the multivariable analysis.
LVMI <25th percentile (log rank test 8.06, P = 0.004)
(Fig. 2A). Similarly, the rate of increase in LVMI was sig-
nificantly higher (P = 0.029) in patients with incident fatal
and nonfatal cardiovascular events (0.25 g/m2.7/month,
0.04 to 0.71 g/m2.7/month) than in those without such
events (0.14 g/m2.7/month, −0.16 to 0.44 g/m2.7/month).
Accordingly, the relative risk of adverse cardiovascular
outcomes was s higher (HR 2.01, 95% CI 1.46–2.54) in
patients with changes in LVMI above the 75th percentile
than in those with changes below the 25th percentile (log
rank test 8.31, P = 0.004) (Fig. 2B).
LVH progression, all-cause death, and cardiovascular
morbidity: Univariate and multivariate Cox
regression analysis
On univariate analysis, besides changes in LVMI, also
age, gender, smoking, previous cardiovascular events,
baseline LVMI and plasma norepinephrine resulted to be
significantly associated to incident all cause mortality (all
P < 0.05). When we tested the predictive power of all uni-
variate predictors of survival by a backward elimination
strategy, only variables listed in Table 2 maintained an
independent association with the outcome. In this model
we forced also baseline LVMI to control for regression to
the mean. By this analysis we found that the progression
of LVH was significantly related to all-cause mortality
(Table 2). By the same token, changes in LVMI resulted to
be an independent predictor of fatal and nonfatal cardio-
vascular events in a Cox model, including age, smoking,
diabetes, previous cardiovascular events, baseline LVMI,
and plasma ADMA (Table 3).
DISCUSSION
This study shows that progression of LVH in patients
with ESRD is associated with mortality and incident
cardiovascular events independently of baseline LVM
and of traditional and emerging risk factors. This find-
ing indicates that monitoring LVM by echocardiography
provides significant prognostic information respect to a
single estimate of LVM and suggests that repeated mea-
surements may be useful in clinical practice in the man-
agement of ESRD patients. LVH is perhaps the most
powerful indicator of mortality and cardiovascular com-
plications in patients with chronic renal failure [5]. Sev-
eral mechanisms may contribute to explain the increased
risk associated with LVH. LVH is associated with myocar-
dial fibrosis and diastolic dysfunction which is an impor-
tant factor in the evolution of heart failure. Furthermore
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Table 3. Multivariate analysis of fatal and nonfatal cardiovascular events
Units of increase Hazard ratio (95% CI) P value
Changes in LVMI
<25th percentile <−0.10 g/m2.7/month 1a
25–75th percentile −0.10- 0.50 g/m2.7/month 1.48 (0.73–2.99) 0.28
>75th percentile >0.50 g/m2.7/month 3.02 (1.44–6.34) 0.003
Age 1 year 1.04 (1.02–1.06) <0.001
Smoking 1.95 (1.18–3.25) 0.01
Diabetes 2.55 (1.33–4.91) 0.005
Previous cardiovascular eventsb 1.78 (1.08–2.93) 0.02
Baseline LVMI 1.00 (0.99–1.01) 0.97
ADMA 1 lmol/L 1.20 (1.04–1.38) 0.01
LVMI is left ventricular mass index; ADMA is asymmetrical dimethylarginine.
aReference group.
bEvents occurring in between the two echocardiographic studies were considered (together with cardiovascular events that occurred before the study) as “previous
cardiovascular events” and this variable was introduced into the multivariable analysis.
LVH reduces coronary reserve and induces cardiac is-
chemia which may in turn promote myocardial infarction
and lethal arrhythmias. The problem of whether progres-
sion or regression of LVH predicts clinical outcomes is
an important issue in clinical practice because it could
signal an increasing level of risk and may prompt a bet-
ter tailoring of treatments being administered and/or a
closer surveillance. The prognostic importance of changes
in LVM has been established in observational studies in
the general population [13] and in essential hypertensive
patients [14] as well as in the context of large random-
ized clinical trials [19]. Thus progression and reversal of
LVH are solidly linked to parallel changes in major car-
diovascular complications in the general population. The
prognostic value of changes in LVM in ESRD in every-
day clinical practice is still unknown. The issue is impor-
tant because, due to the difference in risk factors and
in background cardiovascular complications [20], results
of studies in the general population cannot be loosely ap-
plied to the dialysis population. An elegant multifactorial
intervention trial by London et al [4] has demonstrated
that LVH regression is strongly associated with reduced
mortality in dialysis patients. In clinical practice, adher-
ence to treatment and clinical monitoring are much less
accurate than during clinical trials and it is well known
that patients enrolled in clinical trials may not be rep-
resentative of the parent population. Although inferior
to clinical trials to assess the efficacy of treatments, ob-
servational studies provide prognostic information which
better reflect the real world of everyday clinical practice.
In the context of clinical practice in ESRD patients the
prognostic value of changes in LVM cannot be taken for
granted. Indeed, LVH progression was associated with a
difference of marginal statistical significance in the inci-
dence rate of cardiac failure in an observational study by
Foley et al [12], while there is presently no observational
study linking LVH progression to mortality in ESRD pa-
tients. In testing the prognostic value of repeated mea-
surements of any putative risk factor or risk marker it
is important accounting for the baseline estimate of the
factor being tested. Indeed, owing to measurement er-
ror, extreme values tend to be less extreme when the
measurement is replicated (regression to the mean), a
phenomenon that was very evident in our cohort. The
fact that progression of LVH was strongly linked to subse-
quent mortality and cardiovascular events independently
of baseline LVMI and of a large series of traditional and
emerging risk factors is of relevance because it indicates
that assessing changes in LVMI is at least as important as
estimating LVMI. Like in the study by Foley et al [12], we
found that LVH worsens with time. Indeed, in our cohort
LVMI increased by 7% in the second study performed
about 11/2 years after the baseline study. This finding in-
dicates that management of risk factors for LVH was un-
satisfactory in our patients and that there is ample room
for improvement. Our analysis coherently suggests that
changes in LVM represent a stronger predictor for mor-
tality and CV complications than LVMI itself and sug-
gests that periodic echocardiographic studies are useful
in patients with ESRD. Our study has limitations. Due to
mortality and censoring, about 25% of patients could not
repeat echocardiography. Thus, the cohort that entered
the follow-up study aimed at establishing the prognostic
value of serial echocardiographic studies had a lower risk
than the original cohort and therefore it imperfectly re-
flects risk factors for LVH in the dialysis population. A
shorter time interval between the two echocardiographic
studies could have limited this problem but the shorter
the time interval the less likely registering meaningful
changes in LVMI in the absence of an articulated in-
tervention plan. Thus, our study suggests that repeating
echocardiography after about 11/2 years is useful for risk
stratification but it remains to be studied whether shorter
echocardiographic monitoring of LVM conveys compa-
rable prognostic information.
The second limitation derives from the fact that
LVMI measurements in the CREED cohort were
made by two cardiologists who carefully calibrated
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echocardiographic measurements on the basis of estab-
lished standards. In clinical practice echocardiographic
measurements of LVMI made by different sonographers
in different institutions may be less reliable. Further-
more, it still remains to be demonstrated that repeated
LVMI measurements have a favorable impact in the
management of ESRD. The efficacy of a clinical policy
contemplating serial LVMI measurements in ESRD pa-
tients remains to be formally tested in a randomized clin-
ical trial, which is the gold standard for establishing the
value of clinical tests.
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